Ebola drug, ZMapp, gets FDA Fast Track Status

LeafBio, Inc. (LeafBio), the commercial arm of Mapp Biopharmaceutical, Inc. (Mapp), announced last week that the U.S. Food and Drug Administration (FDA) has granted ZMappa "Fast Track" designation for the treatment of Ebola virus disease. "Fast Track" designation is granted to drugs that the FDA determines, based on nonclinical or clinical data, have the potential to ["]